For those members of this forum interested in the use of lutetium and where it 'fits' in the treatment of prostate cancer, this webinar from the Prostate Theranostics Imaging Centre of Excellence and the International Cancer Imagining Society is sure to be of interest.
The discussion will focus on the ground -breaking advancements in Lutetium -177 PSMA Theranostics, particularly its potential as an earlier line of therapy. A focus of the presentation will be the unpacking of the exciting findings of PSMAfore and ENZA-P trials by Professors Louise Emmett and Oliver Sartor. Both Louise and Oliver will provide comprehensive summaries and insights into these pivotal studies.
Additionally, the webinar will offer a unique platform for diverse perspectives from various Asian countries on the current applications and future of PSMA PET/CT and PSMA theranostics. It will provide the opportunity to hear from experts from many Asian countries and around the globe. Broadcast live from the GU Cast studio in Melbourne.
Marnie - Thanks for the advance heads-up on the webinar. I expect this will advance the info shared by Drs. Emmett and Sartor in the video interview you linked in an earlier post. In that interview, Dr. Emmett was very impressive and it seems she has firmly established herself as a leader in applied PSMA theranostics.
FWIW, at my late 2023 appointment with my MO, I asked about the cost for Pluvicto without insurance coverage (i.e., Hormone Sensitive status) and outside of a clinical trial and he quoted the round number of $100K. (I didn't ask if that was for a single treatment or a series, as in my case I wouldn't have made much difference!)
Give our best to Ron and Y'all Stay S&W. Ciao - Capt'n cujoe
The cost of my very effective (so far) treatments with Lu-PSMA-J591 in Perth AU last year by Nat Lenzo was about $11,000 US for both doses and all associated care. Flights, hotels and meals were extra but amazing hospitality graciously and new friendships provided free.
Paul, do you know if there is anything published by now on the elimination of micromets following SBRT with the kind of treatment you had?Great that your pioneering treatment seems to be working!
Paul - Thanks for providing some international (and personal) perspective on the availablility of PSMA theranostics for HS patients. It also illustrates that the "free-market" is more free in some parts of the world than it is in others.
Enjoy the sun, sand, and beach - while being and staying S&W, Ciao - cujoe
I had two doses of Lu-J591 in May 2022 (4 weeks after SBRT to 2 LNs). MY PSA dropped by 90% in first few months then continued to decline to non-detectable (<0.014) where it remains. So: Very effective!
Thanks for posting this information. As new treatments develop, there is the continued trend of moving it from MCRPC to the MHSPC patients. Would using Lutetium-PSMA earlier result in achieving a 50% survival rate for 5 years for Stage IV PCa?? I believe so...
Unfortunately, these things take time...
I'll sign up and see about watching some of these... I like Ollie and Louise..
Me too Dave. I think they both have a lot to offer.
Declan Murphy, (one of those involved) said in an email that the webinar will also eventually make its way onto his podcast. I'll post the link to that when it's up and running. Hope all goes well in WV.
Well there you go, Sartor's brief presentation on PSMAFore and PSMA-DC make's the case (so far) to not wait. Sequence Lu177 before other systemic treatments. As long as renal function and blood counts are acceptable. (Hi Marnie ❤️)
The only reason that we are forced to wait is the system... Oz pushing it to the MHSPC level just makes sense... If it works on resistant disease, how much better on the sensitive disease version... Such logic....shocking !!! Glad to hear that you are doing well after your treatment, and still running undetectable on the PSA..
G'day Paul. I thought something that was very interesting and encouraging at the end of Sartor's presentation was that he made a small reference to working towards finding ways to avoid ADT. I've just sent you an email re Michael Hofman..😘
The PSMA-DC study Oliver Sartor described fits the treatment I had (except monoclonal antibidy J591) for oligometastatic hormone sensitive PC. Still no sign of failure with PSA undetectable. Hugs. Paul
I wrote in my contact details to see the webinar now, but a password is required to access it. Do you know how to get around this? Or could you sum up what the conclusions are - the earlier LU-177 the better, before castration resistance and before chemo?
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
